Speaking of TSLA, Consumer Reports just named the Tesla Model S best car buy of the year (again) with a 99/100 score
If you mean the pulmonary, pain and oncology products, it will take that long to go through the approval process but not as long as it might have because with Afrezza/Technosphere you have proof of concept established, and whatever drugs they plan to adapt have already been shown to be safe in their current format.
1. Transaction occurred pursuant to Rule 10B5-1 Plan.
2. The reporting person was granted restricted stock units that vest upon the achievement of certain defined performance milestones. On February 3, 2015, the last defined performance milestone was met, resulting in the vesting of the restricted stock units.
3. Shares withheld to satisfy the tax liability to the vesting of a restricted stock unit award.
Levemir was approved by the FDA in 2005 -- 10 YEARS AGO.It first appeared in Europe, Switzerland to be exact, on March 1 2004, launched in other European countries over the rest of 2004 into 2005. Its approved use was expanded for children in 2012.
Afrezza was approved LAST JUNE and was just released this month. Can we get a foot from shore before people start yammering about advertising? It's a different world, and Twitter feeds and YouTube videos are already spreading the word, along with a world class sales force behind it.
I find it hysterically funny he thinks the new Sanofi chief should quick sever any connection with Afrezza, get out of the agreement right away to protect Sanofi from the problems Pfizer had with Exubera. And sales are disappointing already.
Not even close. Aside from the HUGE differences in the inhaler itself, more important are the pharmacodynamics and pharmacokinetics of the two.
Repost of kevinmik:
Pfizer launched Exubera in the United States in early 2007 and 10 months later they withdrew the drug off the market for commercialization reasons in October 2007. Exubera U.S., weekly Trx never got above the 1800's and the drug only generated a total of $12 million in sales over the 10 months. It appears Pfizer was able to made some head way on Nrx each week, but many patients chose not refill their prescriptions after trying it.
Here is Trx numbers for Exubera 1/2 way into its launch in 2007, which were pretty pathetic.
5/04/2007 = 1,664 Trx
5/11/2007 = 1,670 Trx
5/18/2007 = 1,659 Trx
5/25/2007 = 1,816 Trx
6/22/2007 = 1.883 Trx
6/29/2007 = 1.858 Trx
mine seems to be hitting "ignore" on more and more posters & IDs - it's at least a part-time job these days.
Not yet showing on their website/calendar so if the report is the 17th it should be there already as they usually post about a week beforehand. So maybe the 24th.
I don't even bother reading them. If "shaggy" is anywhere in the name it goes on ignore automatically.